Basic Information
| LncRNA/CircRNA Name | DDX11-AS1 |
| Synonyms | NA |
| Region | GRCh38_12:31020763-31073847 |
| Ensemble | ENSG00000245614 |
| Refseq | NR_038927 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | esophageal cancer |
| ICD-0-3 | C15 |
| Methods | RT-qPCR, Western blot, RIP |
| Sample | EC tissues,cell line |
| Expression Pattern | up-regulated |
| Function Description | DDX11-AS1 knockdown results in reduced resistance of EC cells to PTX by inhibiting TOP2A transcription via TAF1. Therefore, DDX11-AS1 knockdown could be a promising therapeutic strategy for EC. |
| Pubmed ID | 31720085 |
| Year | 2019 |
| Title | The resistance of esophageal cancer cells to paclitaxel can be reduced by the knockdown of long noncoding RNA DDX11-AS1 through TAF1/TOP2A inhibition |
External Links
| Links for DDX11-AS1 | GenBank HGNC NONCODE |
| Links for esophageal cancer | OMIM COSMIC |